Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.55 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 3/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2437107 | 0.90 | EGLN1 (0.68) | EGLN1METAP2HIF1AALDH1A1 | |
| SCHEMBL2436274 | 0.81 | EGLN1 (0.58) | EGLN1METAP2HIF1AALDH1A1GSK3B | |
| SCHEMBL2435696 | 0.81 | EGLN1 (0.71) | EGLN1HIF1AALDH1A1MEN1NPC1 | |
| SCHEMBL2438424 | 0.81 | EGLN1 (0.74) | EGLN1HIF1AALDH1A1MEN1NPC1 | |
| SCHEMBL2440161 | 0.80 | EGLN1 (0.48) | EGLN1METAP2HIF1AALDH1A1GSK3B | |
| SCHEMBL2438583 | 0.78 | EGLN1 (0.61) | EGLN1HIF1AALDH1A1NPC1 | |
| SCHEMBL2434562 | 0.74 | EGLN1 (0.64) | EGLN1HIF1AALDH1A1GSK3B | |
| SCHEMBL2439979 | 0.74 | EGLN1 (0.63) | EGLN1HIF1AALDH1A1GSK3BMEN1 | |
| SCHEMBL12291923 | 0.72 | EGLN1 (0.76) | EGLN1HIF1AALDH1A1MEN1NPC1 | |
| SCHEMBL2438080 | 0.72 | EGLN1 (0.61) | EGLN1HIF1AALDH1A1MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142509-B1 | QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | AMGEN INC (US) | 2013-12-04 | — | — | EP | disclosed |
| US-8349868-B2 | Azaquinolones that inhibit prolyl hydroxylase | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8048894-B2 | Quinolones and azaquinolones that inhibit prolyl hydroxylase | AMGEN INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110224248-A1 | AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | AMGEN INC. (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2142509-A2 | QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | Amgen, Inc (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090156605-A1 | Quinolones and azaquinolones that inhbit prolyl hydroxylase | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008130600-A2 | QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | AMGEN INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156605-A1 | Quinolones and azaquinolones that inhbit prolyl hydroxylase | EGLN3, HIF1AN, EGLN2 | EGLN1 6/4885METAP2 2650/4885ERN1 3894/4885 |
| US-20110224248-A1 | AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | HIF1AN, EGLN3, EGLN2 | EGLN1 6/4885METAP2 2895/4885ERN1 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.